We are working closely within international consortia – BSL4ZNet and EVAg – to share information on activity, best practice and reagents and materials, including SARS CoV-2 viruses. This will ensure we do not compete or duplicate our research and development efforts.
We are establishing a partnership with the Peter Doherty Institute to test candidate antiviral compounds from international manufacturers.
We have represented Australia in a World Health Organisation meeting on COVID-19.
We are in dialogue with several international consortia in establishing novel diagnostic capability.
We have received funding from the Coalition for Epidemic Preparedness Innovations (CEPI), a global group that aims to speed up the development of vaccines and cut short the COVID-19 pandemic.
We have commenced testing candidate vaccines from the University of Oxford (UK) and Inovio Pharmaceuticals Inc (US). This work is expected to take around three months and is being conducted at the Australian Centre for Disease Preparedness in Geelong.